Alpha Teknova, Inc. (TKNO)

↓ Download CSV

CIK 0001850902 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Alpha Teknova, Inc. reported revenue of $40.52M, up 7.4% from the prior year. The company ran a net loss, with a net margin of -42.6% and a gross margin of 33.2%. It held $103.58M in total assets against $34.81M in total liabilities.

Key ratios (FY2025)

33.2%
Gross margin
-41.9%
Operating margin
-42.6%
Net margin
-25.1%
Return on equity
+7.4%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019
Revenue$40.52M$37.74M$36.68M$41.42M$36.89M$31.30M
Cost of Revenue$27.08M$30.51M$26.39M$23.94M$19.27M$13.54M
Gross Profit$13.44M$7.23M$10.30M$17.48M$17.62M$17.75M
Operating Income-$16.98M-$26.15M-$35.56M-$49.66M-$12.01M$4.66M
Net Income-$17.26M-$26.75M-$36.78M-$47.47M-$9.80M$3.57M
EPS (Diluted)$-0.32$-0.57$-1.16$-1.69$-0.61$0.16
Total Assets$103.58M$118.77M$128.59M$152.26M$166.51M$62.91M
Total Liabilities$34.81M$36.38M$38.55M$52.38M$23.31M$10.51M
Shareholders' Equity$68.78M$82.39M$90.04M$99.89M$143.20M$16.77M$12.91M
Cash & Equivalents$5.91M$3.71M$28.48M$42.24M$87.52M$3.31M$4.14M
Operating Cash Flow-$8.65M-$12.39M-$18.81M-$27.40M-$9.07M$2.50M
Capital Expenditures$1.15M$1.12M$7.93M$28.15M$19.88M$5.47M
Shares Outstanding53.56M53.41M40.79M28.18M28.01M3.60M